A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT

Journal of Cutaneous Pathology

Volumn 42, Issue 2, 2015, Pages 108-117

  Hosler, Gregory A ^a,b   Davoli, Teresa ^c   Mender, Ilgen ^d   Litzner, Brandon ^a   Choi, Jaehyuk ^e   Kapur, Payal ^a   Shay, Jerry W ^d   Wang, Richard C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ProPath   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF; CDKN2A; FISH; melanoma; TERT

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; TELOMERASE; TERT PROTEIN, HUMAN;

ADULT; CASE REPORT; FEMALE; FOLLOW UP; GENETICS; HUMAN; MELANOMA; MENINGIOMA; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SECONDARY; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; BASE SEQUENCE; FEMALE; FOLLOW-UP STUDIES; GENES, P16; HUMANS; MELANOMA; MENINGEAL NEOPLASMS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE; YOUNG ADULT;

EID: 84923480277     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12444     Document Type: Article

References (52)

1. Yazdan P, Cooper C, Sholl LM, et al. Comparative analysis of atypical spitz tumors with heterozygous versus homozygous 9p21 deletions for clinical outcomes, histomorphology, BRAF mutation, and p16 expression. Am J Surg Pathol 2014; 38: 638.
2. Fullen DR, Poynter JN, Lowe L, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 2006; 19: 1324.
3. Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol 2012; 36: 818.
4. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33: 19.
5. Yeh I, von Deimling A, Bastian BC,. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. J Natl Cancer Inst 2013; 105: 917.
6. Bastian BC,. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014; 9: 239.
7. Hill VK, Gartner JJ, Samuels Y, Goldstein AM,. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet 2013; 14: 257.
8. Conway C, Beswick S, Elliott F, et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer 2010; 49: 425.
9. Gerami P, Scolyer RA, Xu X, et al. Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol 2013; 37: 676.
10. Grafstrom E, Egyhazi S, Ringborg U, Hansson J, Platz A,. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin Cancer Res 2005; 11: 2991.
11. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000; 60: 1968.
12. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA,. Highly recurrent TERT promoter mutations in human melanoma. Science 2013; 339: 957.
13. Heidenreich B, Nagore E, Rachakonda PS, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 2014; 5: 3401.
14. Griewank KG, Murali R, Puig-Butille JA, et al. TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. J Natl Cancer Inst 2014; 106: 9.
15. Buresh CJ, Oliai BR, Miller RT,. Reactivity with TdT in Merkel cell carcinoma: a potential diagnostic pitfall. Am J Clin Pathol 2008; 129: 894.
16. Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44: 751.
17. Koelsche C, Sahm F, Capper D, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013; 126: 907.
18. Suram A, Kaplunov J, Patel PL, et al. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J 2012; 31: 2839.
19. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012; 30: 2522.
20. Satzger I, Degen A, Asper H, Kapp A, Hauschild A, Gutzmer R,. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 2013; 31: e220.
21. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011; 43: 1018.
22. Gammon B, Traczyk TN, Gerami P,. Clumped perinuclear BAP1 expression is a frequent finding in sporadic epithelioid Spitz tumors. J Cutan Pathol 2013; 40: 538.
23. Gerami P, Li G, Pouryazdanparast P, et al. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol 2012; 36: 808.
24. Takai H, Smogorzewska A, de Lange T,. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13: 1549.
25. Warters RL, Adamson PJ, Pond CD, Leachman SA,. Melanoma cells express elevated levels of phosphorylated histone H2AX foci. J Invest Dermatol 2005; 124: 807.
26. Straume O, Sviland L, Akslen LA,. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6: 1845.
27. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29: 1239.
28. Bauer J, Buttner P, Murali R, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345.
29. Nagore E, Requena C, Traves V, et al. Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol 2014; 70: 858.
30. Robles-Espinoza CD, Harland M, Ramsay AJ, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 2014; 46: 478.
31. Shi J, Yang XR, Ballew B, et al. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet 2014; 46: 482.
32. Han J, Qureshi AA, Prescott J, et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol 2009; 129: 415.
33. Nan H, Du M, De Vivo I, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res 2011; 71: 6758.
34. Lisaingo K, Uringa EJ, Lansdorp PM,. Resolution of telomere associations by TRF1 cleavage in mouse embryonic stem cells. Mol Biol Cell 2014; 25: 1958.
35. Kim MK, Smith S,. Persistent telomere cohesion triggers a prolonged anaphase. Mol Biol Cell 2014; 25: 30.
36. McKerlie M, Walker JR, Mitchell TR, Wilson FR, Zhu XD,. Phosphorylated (pT371)TRF1 is recruited to sites of DNA damage to facilitate homologous recombination and checkpoint activation. Nucleic Acids Res 2013; 41: 10268.
37. Hockemeyer D, Daniels JP, Takai H, de Lange T,. Recent expansion of the telomeric complex in rodents: two distinct POT1 proteins protect mouse telomeres. Cell 2006; 126: 63.
38. Hayashi MT, Cesare AJ, Fitzpatrick JA, Lazzerini-Denchi E, Karlseder J,. A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nat Struct Mol Biol 2012; 19: 387.
39. Davoli T, de Lange T,. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell 2012; 21: 765.
40. Davoli T, de Lange T,. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol 2011; 27: 585.
41. Isaac AK, Lertsburapa T, Pathria Mundi J, Martini M, Guitart J, Gerami P,. Polyploidy in spitz nevi: a not uncommon karyotypic abnormality identifiable by fluorescence in situ hybridization. Am J Dermatopathol 2010; 32: 144.
42. Satoh S, Hashimoto-Tamaoki T, Furuyama J, Mihara K, Namba M, Kitano Y,. High frequency of tetraploidy detected in malignant melanoma of Japanese patients by fluorescence in situ hybridization. Int J Oncol 2000; 17: 707.
43. Gattuso P, Reddy V, Solans E, et al. Is DNA ploidy of prognostic significance in stage I cutaneous melanoma? Surgery 1990; 108: 702.
44. Vogt T, Stolz W, Glassl A, et al. Multivariate DNA cytometry discriminates between Spitz nevi and malignant melanomas because large polymorphic nuclei in Spitz nevi are not aneuploid. Am J Dermatopathol 1996; 18: 142.
45. LeBoit PE, Van Fletcher H,. A comparative study of Spitz nevus and nodular malignant melanoma using image analysis cytometry. J Invest Dermatol 1987; 88: 753.
46. Kheir SM, Bines SD, Vonroenn JH, Soong SJ, Urist MM, Coon JS,. Prognostic significance of DNA aneuploidy in stage I cutaneous melanoma. Ann Surg 1988; 207: 455.
47. Solimini NL, Xu Q, Mermel CH, et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 2012; 337: 104.
48. Davoli T, Xu AW, Mengwasser KE, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell 2013; 155: 948.
49. Shay JW, Wright WE,. Role of telomeres and telomerase in cancer. Semin Cancer Biol 2011; 21: 349.
50. Shay JW, Wright WE,. Telomeres and telomerase: implications for cancer and aging. Radiat Res 2001; 155 (1 Pt 2): 188.
51. Shay JW,. Are short telomeres predictive of advanced cancer? Cancer Discov. 2013; 3: 1096.
52. Artandi SE, DePinho RA,. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000; 10: 39.